Sanofi (SNY) Misses on Q4 Earnings and Sales, Stock Down
https://www.zacks.com/stock/news/2219619/sanofi-sny-misses-on-q4-earnings-and-sales-stock-down?cid=CS-ZC-FT-analyst_blog|earnings_article-2219619
Feb 01, 2024 - Sanofi (SNY) misses fourth-quarter estimates for earnings and sales. It maintains 2024 earnings growth guidance.
0
Novo Nordisk (NVO) Q4 2023 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2024/01/31/novo-nordisk-nvo-q4-2023-earnings-call-transcript/?source=iedfolrf0000001
Jan 31, 2024 - NVO earnings call for the period ending December 31, 2023.
0
ADP Cools to 107K Private-Sector Jobs; BA, NVO Beat in Q4
https://www.zacks.com/stock/news/2218851/adp-cools-to-107k-private-sector-jobs-ba-nvo-beat-in-q4?cid=CS-ZC-FT-ahead_of_wall_street-2218851
Jan 31, 2024 - We've now spent a full six months sub-200K private-sector job gains per month.
0
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
https://www.zacks.com/stock/news/2218712/are-you-a-growth-investor-this-1-stock-could-be-the-perfect-pick?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_growth_score-2218712
Jan 31, 2024 - Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
0
Big Earnings Afternoon: Microsoft, Alphabet, Starbucks & More
https://www.zacks.com/stock/news/2218328/big-earnings-afternoon-microsoft-alphabet-starbucks-more?cid=CS-ZC-FT-ahead_of_wall_street-2218328
Jan 30, 2024 - Microsoft, Google-parent Alphabet, Mondelez and Skyworks all topped earnings expectations.
0
Top Stock Reports for Apple, Visa & Novo Nordisk
https://www.zacks.com/commentary/2217814/top-stock-reports-for-apple-visa-novo-nordisk?cid=CS-ZC-FT-research_daily-2217814
Jan 30, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Visa Inc. (V) and Novo Nordisk A/S (NVO).
0
What are the Major Stock Market Risks for 2024?
https://www.zacks.com/commentary/2216190/what-are-the-major-stock-market-risks-for-2024?cid=CS-ZC-FT-spoken_word-2216190
Jan 25, 2024 - After Davos is over, let's prognosticate from the cheap seats.
0
Novartis (NVS) to Report Q4 Earnings: Is a Beat in Store?
https://www.zacks.com/stock/news/2215142/novartis-nvs-to-report-q4-earnings-is-a-beat-in-store?cid=CS-ZC-FT-analyst_blog|earnings_preview-2215142
Jan 24, 2024 - Novartis' (NVS) key drugs, Entresto, Kisqali and Pluvicto, are likely to have fueled its top and bottom-line numbers in the fourth quarter.
0
Inhibrx (INBX) Up 6% on Sale of Rare Disease Drug to Sanofi
https://www.zacks.com/stock/news/2214518/inhibrx-inbx-up-6-on-sale-of-rare-disease-drug-to-sanofi?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2214518
Jan 23, 2024 - Sanofi (SNY) will acquire Inhibrx (INBX) for nearly $2.2 billion. Post-acquisition, it will retain the rare disease drug and spin out all other pipeline programs into a newly-traded public company.
0
Novo Nordisk (NVO) Stock Dips While Market Gains: Key Facts
https://www.zacks.com/stock/news/2213778/novo-nordisk-nvo-stock-dips-while-market-gains-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2213778
Jan 22, 2024 - Novo Nordisk (NVO) reachead $105.49 at the closing of the latest trading day, reflecting a -1.37% change compared to its last close.
0